BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mahmoud R, van Lieshout C, Frederix GWJ, Jharap B, Oldenburg B. Continuation of Anti-TNF in Patients With Ulcerative Colitis in Remission Is Not Cost-effective Compared With Treatment Withdrawal: A Markov Model. J Crohns Colitis 2021;15:709-18. [PMID: 33125060 DOI: 10.1093/ecco-jcc/jjaa219] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Stoker AMH, Logghe L, van der Ende-van Loon MCM, Schoon EJ, Schreuder RM, Stronkhorst A, Gilissen LPL. Relapse rates after withdrawal versus maintaining biologic therapy in IBD patients with prolonged remission. Clin Exp Med 2023;:1-9. [PMID: 36633694 DOI: 10.1007/s10238-023-00994-6] [Reference Citation Analysis]
2 Darlington M, Scarica R, Chavez-Pacheco X, Blamplain Segar L, Durand-Zaleski I. Decrementally cost-effective health technologies in non-inferiority studies: A systematic review. Front Pharmacol 2022;13:1025326. [PMID: 36545305 DOI: 10.3389/fphar.2022.1025326] [Reference Citation Analysis]
3 Cortesi PA, Fiorino G, Peyrin-Biroulet L, Mantovani LG, Jairath V, Paridaens K, Andersson FL, Danese S. Non-invasive monitoring and treat-to-target approach are cost-effective in patients with mild-moderate ulcerative colitis. Aliment Pharmacol Ther 2022. [PMID: 36377366 DOI: 10.1111/apt.17261] [Reference Citation Analysis]